

ASX Release

Issued 11 August 2017

Trading Update

Sigma Healthcare Limited (Sigma) has previously advised that current year sales are more challenging given general industry conditions and our ongoing focus on enforcing consistent brand standards to improve brand performance.

In this context, Sigma now anticipates that 1H18 underlying EBIT will be around \$44m, with FY2018 underlying EBIT expected to be around \$90m. This compares to current market consensus for FY18 of approximately \$95m underlying EBIT.

Steps have been taken to enhance sales performance and market share growth in the second half to help overcome the impact of general market conditions and provide momentum into FY2019. This will continue to drive stronger like for like performance from Sigma's brands.

"Sigma delivered above guidance growth in FY17 and remains confident that our business strategy and increased investment in infrastructure will deliver growth and efficiency improvements beyond the current year," Sigma CEO and Managing Director Mark Hooper said.

Full details will be provided at the announcement of our half year results which is scheduled for 7 September 2017.

Contact:

Gary Woodford
Corporate Affairs Manager
Sigma Healthcare Limited
gary.woodford@sigmahealthcare.com.au
0417 399 204 | 03 9215 9632